These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 11602221

  • 1. The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4.
    Le Mellédo JM, Arthur H, Dalton J, Woo C, Lipton N, Bellavance F, Koszycki D, Boulenger JP, Bradwejn J.
    J Psychosom Res; 2001 Sep; 51(3):513-20. PubMed ID: 11602221
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of rats. Part A.
    Wiśniewska RJ.
    Pol J Pharmacol; 1998 Sep; 50(3):203-12. PubMed ID: 9861628
    [Abstract] [Full Text] [Related]

  • 4. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
    Bradwejn J, Koszycki D, Couëtoux du Tertre A, van Megen H, den Boer J, Westenberg H.
    Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
    [Abstract] [Full Text] [Related]

  • 5. Aging and panicogenic response to cholecystokinin tetrapeptide: an examination of the cholecystokinin system.
    Flint A, Bradwejn J, Vaccarino F, Gutkowska J, Palmour R, Koszycki D.
    Neuropsychopharmacology; 2002 Oct; 27(4):663-71. PubMed ID: 12377403
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of aging on cholecystokinin-induced panic.
    Flint AJ, Koszycki D, Vaccarino FJ, Cadieux A, Boulenger JP, Bradwejn J.
    Am J Psychiatry; 1998 Feb; 155(2):283-5. PubMed ID: 9464213
    [Abstract] [Full Text] [Related]

  • 8. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of diabetic rats. Part B.
    Wiśniewska RJ.
    Pol J Pharmacol; 1998 Feb; 50(3):213-23. PubMed ID: 9861629
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interaction of cholecystokinin (CCK-8) with agonist and antagonist of beta-adrenergic receptors in circulatory system of diabetic rats.
    Wiśniewska RJ, Wiśniewski K.
    Pol J Pharmacol; 1996 Feb; 48(3):293-7. PubMed ID: 9112665
    [Abstract] [Full Text] [Related]

  • 11. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
    Katzman MA, Duffin J, Shlik J, Bradwejn J.
    Neuropsychopharmacology; 2002 Jun; 26(6):824-31. PubMed ID: 12007753
    [Abstract] [Full Text] [Related]

  • 12. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls.
    Koszycki D, Torres S, Swain JE, Bradwejn J.
    Psychosom Med; 2005 Jun; 67(4):590-5. PubMed ID: 16046372
    [Abstract] [Full Text] [Related]

  • 13. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
    Bradwejn J, Koszycki D, Annable L, Couëtoux du Tertre A, Reines S, Karkanias C.
    Biol Psychiatry; 1992 Nov 15; 32(10):903-12. PubMed ID: 1467375
    [Abstract] [Full Text] [Related]

  • 14. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers.
    Bradwejn J, Koszycki D, Couëtoux du Tertre A, Paradis M, Bourin M.
    Psychopharmacology (Berl); 1994 Mar 15; 114(2):257-61. PubMed ID: 7838917
    [Abstract] [Full Text] [Related]

  • 15. Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses.
    Riddell JG, Shanks RG.
    Clin Pharmacol Ther; 1985 Nov 15; 38(5):554-9. PubMed ID: 2865028
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder.
    Kellner M, Yassouridis A, Jahn H, Wiedemann K.
    Psychopharmacology (Berl); 1997 Sep 15; 133(1):55-61. PubMed ID: 9335081
    [Abstract] [Full Text] [Related]

  • 18. In vivo beta3-adrenergic stimulation of human thermogenesis and lipid use.
    Schiffelers SL, Blaak EE, Saris WH, van Baak MA.
    Clin Pharmacol Ther; 2000 May 15; 67(5):558-66. PubMed ID: 10824635
    [Abstract] [Full Text] [Related]

  • 19. Reflex vagal withdrawal and the hemodynamic response to intravenous isoproterenol in the presence of beta-antagonists.
    Arnold JM, McDevitt DG.
    Clin Pharmacol Ther; 1986 Aug 15; 40(2):199-208. PubMed ID: 3015474
    [Abstract] [Full Text] [Related]

  • 20. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.
    Maron E, Tõru I, Vasar V, Shlik J.
    J Psychopharmacol; 2004 Jun 15; 18(2):194-9. PubMed ID: 15260907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.